诺唯赞2025年度归母净亏损1697.02万元

Core Viewpoint - The company reported its 2025 annual performance, showing a slight decline in revenue and net profit, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, remaining stable compared to the same period last year [1] - The net profit attributable to the parent company was -16.97 million yuan, and the net profit after deducting non-recurring gains and losses was -79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company reversed previously accrued share-based payment expenses due to not meeting the performance assessment targets of the 2023 restricted stock incentive plan [1] - Additionally, the company, based on a principle of prudence, reversed part of the previously recognized deferred tax assets, leading to an increase in income tax expenses [1]